8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Mar 4, 2026·SEC
PepGen Inc.(PEPG)Earnings, Financials & Key Ratios
PEPG•NASDAQ
$1.85
$127M mkt cap·Price updated May 6, 2026
AboutPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$92M+4.2%
- Net Income-$90M+0.4%
- EPS (Diluted)-2.12+25.6%
- ROE-67.39%+15.0%
- ROIC-73.21%+32.3%
- Debt/Equity0.12-26.7%
PEPG Key Insights
PepGen Inc. (PEPG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 33.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PEPG Price & Volume
PepGen Inc. (PEPG) stock price & volume — 10-year historical chart
Loading chart...
PEPG Growth Metrics
PepGen Inc. (PEPG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.14%
Return on Capital
10 Years-47.49%
5 Years-54%
3 Years-63.65%
Last Year-63.37%
PEPG Recent Earnings
PepGen Inc. (PEPG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
Mar 4, 2026EPS
$0.27
Est $0.40
+32.5%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.52
Est $0.63
+17.5%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.70
Est $0.85
+17.6%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.92
Est $0.72
-27.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 4, 2026 | $0.27vs $0.40+32.5% | — |
| Q4 2025 | Nov 12, 2025 | $0.52vs $0.63+17.5% | — |
| Q3 2025 | Aug 7, 2025 | $0.70vs $0.85+17.6% | — |
| Q2 2025 | May 8, 2025 | $0.92vs $0.72-27.8% | — |
Based on last 12 quarters of dataView full earnings history →
PEPG Peer Comparison
PepGen Inc. (PEPG) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare PEPG vs Peers
PepGen Inc. (PEPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PEPG Income Statement
PepGen Inc. (PEPG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 106K | 0 | 0 | 0 | 1.18M | 1.5M | 1.4M |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -106K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -1.18M▲ 0% | -1.5M▼ 27.1% | -1.4M▲ 7.2% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | - | - | - | -27.11% | 7.18% |
| Operating Expenses | 1.25M | 1.88M | 27.11M | 68.3M | 83.58M | 96.23M | 92.22M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 628K | 853K | 8.11M | 14.22M | 16.64M | 21.26M | 22.57M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 620K | 1.12M | 23.8M | 54.08M | 68.13M | 76.48M | 71.04M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -100K | -4.8M | 0 | -1.18M | -1.5M | -1.4M |
| Operating Income | -1.35M▲ 0% | -1.88M▼ 38.6% | -27.11M▼ 1344.3% | -68.3M▼ 151.9% | -84.77M▼ 24.1% | -97.74M▼ 15.3% | -93.61M▲ 4.2% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -38.63% | -1344.27% | -151.95% | -24.11% | -15.3% | 4.22% |
| EBITDA | -1.25M | -1.77M | -26.93M | -67.81M | -83.58M | -96.23M | -92.22M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -41.59% | -1424.11% | -151.78% | -23.26% | -15.14% | 4.18% |
| D&A (Non-Cash Add-back) | 106K | 110K | 178K | 493K | 1.18M | 1.5M | 1.4M |
| EBIT | -1.35M | -1.88M | -27.11M | -68.3M | -84.77M | -90.6M | -93.61M |
| Net Interest Income | 6K | 8K | 0 | 2.79M | 6.4M | 7.14M | 4.02M |
| Interest Income | 6K | 8K | 0 | 2.79M | 6.4M | 7.14M | 4.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 8K | -12K | -172K | 2.9M | 6.21M | 7.14M | 4.01M |
| Pretax Income | -1.35M▲ 0% | -1.89M▼ 40.3% | -27.28M▼ 1344.2% | -65.4M▼ 139.7% | -78.55M▼ 20.1% | -90.6M▼ 15.3% | -89.61M▲ 1.1% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 3.71M | 73K | -617K | 49K |
| Effective Tax Rate % | 0% | 0% | 0% | -5.67% | -0.09% | 0.68% | -0.05% |
| Net Income | -1.35M▲ 0% | -1.89M▼ 40.3% | -27.28M▼ 1344.2% | -69.1M▼ 153.3% | -78.63M▼ 13.8% | -89.98M▼ 14.4% | -89.66M▲ 0.4% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -40.34% | -1344.2% | -153.3% | -13.78% | -14.44% | 0.36% |
| Net Income (Continuing) | -1.35M | -1.89M | -27.28M | -69.1M | -78.63M | -89.98M | -89.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06▲ 0% | -0.18▼ 199.5% | -1.22▼ 577.8% | -4.42▼ 262.3% | -3.30▲ 25.3% | -2.85▲ 13.6% | -2.12▲ 25.6% |
| EPS Growth % | - | -199.5% | -577.78% | -262.3% | 25.34% | 13.64% | 25.61% |
| EPS (Basic) | -0.06 | -0.53 | -1.22 | -4.42 | -3.30 | -2.85 | -2.12 |
| Diluted Shares Outstanding | 22.39M | 22.39M | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
| Basic Shares Outstanding | 22.39M | 7.72M | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
PEPG Balance Sheet
PepGen Inc. (PEPG) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.77M | 10.32M | 139.99M | 186.08M | 112.68M | 123.76M | 150.96M |
| Cash & Short-Term Investments | 3.49M | 9.78M | 132.9M | 181.75M | 110.41M | 120.19M | 148.46M |
| Cash Only | 3.49M | 9.78M | 132.9M | 181.75M | 80.77M | 49.42M | 60.51M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 29.63M | 70.77M | 87.94M |
| Accounts Receivable | 230K | 407K | 4.74M | 58K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 4.27M | 2.27M | 3.57M | 2.51M |
| Total Non-Current Assets | 419K | 323K | 3.65M | 31.36M | 30.37M | 27.12M | 22.94M |
| Property, Plant & Equipment | 419K | 323K | 636K | 29.88M | 28.38M | 25.15M | 21.02M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 1.47M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 1.55M | 1.47M | 1.99M | 1.97M | 1.92M |
| Total Assets | 4.19M▲ 0% | 10.64M▲ 153.8% | 143.64M▲ 1249.8% | 217.44M▲ 51.4% | 143.05M▼ 34.2% | 150.88M▲ 5.5% | 173.91M▲ 15.3% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 153.8% | 1249.76% | 51.38% | -34.21% | 5.47% | 15.26% |
| Total Current Liabilities | 326K | 838K | 10.32M | 18.83M | 17.53M | 16.7M | 12.65M |
| Accounts Payable | 141K | 721K | 3.24M | 1.36M | 1M | 1.75M | 822K |
| Days Payables Outstanding | 485.52 | - | - | - | 309.82 | 424.9 | 214.77 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.19M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 28K | 1.21M | 2.44M | 2.37M | 3.62M | 8.64M |
| Current Ratio | 11.58x | 12.31x | 13.56x | 9.88x | 6.43x | 7.41x | 11.94x |
| Quick Ratio | 11.58x | 12.31x | 13.56x | 9.88x | 6.43x | 7.41x | 11.94x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 30K | 226K | 18.98M | 17.1M | 15.57M | 13.82M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 13.82M |
| Capital Lease Obligations | 0 | 0 | 0 | 18.98M | 17.1M | 15.57M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 30K | 226K | 0 | 0 | 0 | 0 |
| Total Liabilities | 326K | 868K | 10.55M | 37.81M | 34.63M | 32.26M | 26.46M |
| Total Debt | 0 | 0 | 0 | 24.53M | 20.1M | 18.66M | 17M |
| Net Debt | -3.49M | -9.78M | -132.9M | -157.22M | -60.67M | -30.76M | -43.51M |
| Debt / Equity | - | - | - | 0.14x | 0.19x | 0.16x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | 3.87M▲ 0% | 9.77M▲ 152.8% | 133.09M▲ 1261.7% | 179.63M▲ 35.0% | 108.42M▼ 39.6% | 118.62M▲ 9.4% | 147.44M▲ 24.3% |
| Equity Growth % | - | 152.75% | 1261.71% | 34.97% | -39.64% | 9.41% | 24.3% |
| Book Value per Share | 0.17 | 0.44 | 5.94 | 11.49 | 4.56 | 3.76 | 3.49 |
| Total Shareholders' Equity | 3.87M | 9.77M | 133.09M | 179.63M | 108.42M | 118.62M | 147.44M |
| Common Stock | 0 | 0 | 0 | 2K | 2K | 3K | 7K |
| Retained Earnings | -2.39M | -6.47M | -33.75M | -102.86M | -181.48M | -271.46M | -361.12M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -8K | -8K | 17K | -81K | 34K | 23K | 11K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PEPG Cash Flow Statement
PepGen Inc. (PEPG) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -885K | -1.65M | -22.6M | -59.27M | -69M | -82.37M | -81.64M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -86.67% | -1267.98% | -162.25% | -16.42% | -19.38% | 0.89% |
| Net Income | -1.35M | -1.89M | -27.28M | -69.1M | -78.63M | -89.98M | -89.66M |
| Depreciation & Amortization | 106K | 110K | 178K | 493K | 850K | 5.25M | 5.14M |
| Stock-Based Compensation | 0 | 119K | 1.53M | 4.76M | 7.05M | 11.46M | 10.61M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 59K | 0 | 196K | 76K | -220K | -3.85M | -1.51M |
| Working Capital Changes | 296K | 8K | 2.77M | 4.51M | 1.95M | -5.25M | -6.22M |
| Change in Receivables | -112K | -170K | -4.34M | 4.18M | 26K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 59K | 331K | 2.51M | -1.41M | -369K | 722K | -935K |
| Cash from Investing | -29K | -8K | -500K | -3.75M | -32M | -37.67M | -15.23M |
| Capital Expenditures | -29K | -8K | -500K | -3.75M | -2.6M | -497K | -264K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.79M | 7.95M | 147.66M | 112.19M | -189K | 88.75M | 107.98M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -3K | -1.39M | -2.07M | -189K | 1.97M | 0 |
| Net Change in Cash | 1.88M▲ 0% | 6.29M▲ 235.1% | 124.59M▲ 1881.7% | 48.86M▼ 60.8% | -100.9M▼ 306.5% | -31.35M▲ 68.9% | 11.09M▲ 135.4% |
| Free Cash Flow | -914K▲ 0% | -1.66M▼ 81.6% | -23.1M▼ 1291.5% | -63.02M▼ 172.8% | -71.6M▼ 13.6% | -82.87M▼ 15.7% | -81.9M▲ 1.2% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -81.62% | -1291.51% | -172.83% | -13.61% | -15.75% | 1.17% |
| FCF per Share | -0.04 | -0.07 | -1.03 | -4.03 | -3.01 | -2.62 | -1.94 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.87x | 0.83x | 0.86x | 0.88x | 0.92x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 2.7M | 71K | 0 |
PEPG Key Ratios
PepGen Inc. (PEPG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -34.81% | -27.7% | -38.19% | -44.19% | -54.59% | -79.26% | -67.39% |
| Return on Invested Capital (ROIC) | - | -756.85% | -20853.08% | -453.08% | -181.22% | -108.11% | -73.21% |
| Debt / Equity | - | - | - | 0.14x | 0.19x | 0.16x | 0.12x |
| FCF Conversion | 0.66x | 0.87x | 0.83x | 0.86x | 0.88x | 0.92x | 0.91x |
PEPG SEC Filings & Documents
PepGen Inc. (PEPG) SEC filings — annual & quarterly reports (10-K, 10-Q)
PEPG Frequently Asked Questions
PepGen Inc. (PEPG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PepGen Inc. (PEPG) grew revenue by 0.0% over the past year. Growth has been modest.
PepGen Inc. (PEPG) reported a net loss of $89.7M for fiscal year 2025.
Dividend & Returns
PepGen Inc. (PEPG) has a return on equity (ROE) of -67.4%. Negative ROE indicates the company is unprofitable.
PepGen Inc. (PEPG) had negative free cash flow of $81.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More PEPG
PepGen Inc. (PEPG) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates